Cerity Partners LLC Acquires 189 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Cerity Partners LLC increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,463 shares of the company’s stock after purchasing an additional 189 shares during the quarter. Cerity Partners LLC’s holdings in Medpace were worth $755,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of MEDP. Wellington Management Group LLP boosted its position in shares of Medpace by 312.6% in the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after purchasing an additional 319,210 shares during the period. Invesco Ltd. increased its stake in Medpace by 67.6% in the 3rd quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after buying an additional 246,775 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in Medpace in the 3rd quarter worth $30,252,000. International Assets Investment Management LLC raised its holdings in Medpace by 248,773.8% during the fourth quarter. International Assets Investment Management LLC now owns 104,527 shares of the company’s stock valued at $32,041,000 after acquiring an additional 104,485 shares during the period. Finally, Lord Abbett & CO. LLC lifted its position in shares of Medpace by 682.8% in the third quarter. Lord Abbett & CO. LLC now owns 114,588 shares of the company’s stock valued at $27,745,000 after acquiring an additional 99,949 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

Shares of MEDP opened at $407.15 on Wednesday. The stock has a market capitalization of $12.61 billion, a PE ratio of 45.85, a P/E/G ratio of 1.97 and a beta of 1.38. The company’s fifty day moving average is $397.68 and its 200 day moving average is $323.14. Medpace Holdings, Inc. has a fifty-two week low of $187.03 and a fifty-two week high of $419.42.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The firm had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. During the same period in the previous year, the firm posted $2.27 EPS. The business’s quarterly revenue was up 17.7% on a year-over-year basis. As a group, research analysts forecast that Medpace Holdings, Inc. will post 10.53 earnings per share for the current year.

Insider Buying and Selling at Medpace

In other news, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the transaction, the vice president now owns 15,181 shares in the company, valued at approximately $6,117,943. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Medpace news, Director Ashley M. Keating sold 250 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the transaction, the director now owns 250 shares in the company, valued at $102,467.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The disclosure for this sale can be found here. Insiders have sold a total of 189,340 shares of company stock worth $76,651,647 over the last ninety days. Company insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 target price for the company. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and upped their target price for the stock from $340.00 to $450.00 in a research report on Tuesday. Robert W. Baird boosted their price target on shares of Medpace from $312.00 to $408.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 14th. Finally, UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and raised their price objective for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $395.60.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.